For therapeutic applications, BioPharmX has developed a novel anhydrous topical delivery system for hydrophilic molecules. This delivery system uses an anhydrous gel formulation that allows for the stabilization, adequate solubilization, and rapid absorption of minocycline into the skin rather than remaining on the surface, a common problem with oil-based ointments and suspensions. Due to the nature of the platform design, it may be suitable for multiple APIs. The first molecule being developed using this delivery system is minocycline for both acne and rosacea indications. Minocycline was selected as the first API as it is the most commonly prescribed oral antibiotic for the treatment of these conditions due to its high effectiveness, anti-inflammatory properties, and relatively low antibiotic resistance rate.